ArticleHead & neck2025
Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSquamous cell carcinoma of the soft palate (SCCSP) represents a rare subtype of oropharyngeal cancer. This study aims to evaluate the treatment outcomes of SCCSP and to assess the prognostic significance of HPV status.
methodsPatients diagnosed with SCCSP between January 1981 and December 2021 were collected. Survival outcomes were compared.
resultsIn univariate analysis, primary surgery resulted in superior progression-free survival (PFS), overall survival (OS), and disease-specific survival (DSS) compared with definitive radiotherapy (p < 0.05). Furthermore, multivariate analysis revealed that primary surgery independently correlated with superior PFS (HR = 0.37, p = 0.002), OS (HR = 0.55, p = 0.012), and DSS (HR = 0.45, p = 0.020) in early-stage SCCSPs. Additionally, no significant prognostic differences were observed between HPV/p16 positive and HPV/p16 negative SCCSPs (p > 0.05).
conclusionSurgery yields superior oncological outcomes for early-stage SCCSP patients. HPV status does not demonstrate prognostic significance in SCCSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.